Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Employees - 18000,
CEO - Mr. Daniel P. O'Day,
Sector - Healthcare,
Country - US,
Market Cap - 117.24B
Altman ZScore(max is 10): 2.85, Piotroski Score(max is 10): 8, Working Capital: $3054000000, Total Assets: $54525000000, Retained Earnings: $11073000000, EBIT: 1157000000, Total Liabilities: $36135000000, Revenue: $28295000000
AryaFin Target Price - $244.44 - Current Price $92.57 - Analyst Target Price $99.21
Ticker | GILD |
Index | NDX, S&P 500 |
Curent Price | 92.57 |
Change | 1.62% |
Market Cap | 117.24B |
Average Volume | 6.69M |
Income | 126.00M |
Sales | 28.27B |
Book Value/Share | 14.83 |
Cash/Share | 5.29 |
Dividend Est | 3.06 (3.31%) |
Dividend TTM | 3.08 (3.33%) |
Dividend Ex-Date | Dec 13, 2024 |
Employees | 18000 |
Moving Avg 20days | 0.65% |
Moving Avg 50days | 2.30% |
Moving Avg 200days | 20.24% |
Shares Outstanding | 1.25B |
Earnings Date | Nov 06 AMC |
Inst. Ownership | 85.34% |
Price/Earnings | 1043.63 |
Forwad P/E | 12.23 |
PE Growth | 111.52 |
Price/Sales | 4.15 |
Price/Book | 6.24 |
Price/Cash | 17.51 |
Price/FCF | 12.43 |
Quick Ratio | 1.10 |
Current Ratio | 1.26 |
Debt/Equity | 1.26 |
Return on Assets | 0.22% |
Return on Equity | 0.62% |
Return on Investment | 0.32% |
Gross Margin | 77.96% |
Ops Margin | 37.45% |
Profit Margin | 0.45% |
RSI | 54.42 |
BETA(β) | 0.20 |
From 52week Low | 49.14% |
From 52week High | -6.40% |
EPS | 0.09 |
EPS next Year | 7.57 |
EPS next Qtr | 1.72 |
EPS this Year | -34.72% |
EPS next 5 Year | 9.36% |
EPS past 5 Year | 1.55% |
Sales past 5 Year | 4.16% |
EPS Y/Y | -97.87% |
Sales Y/Y | 3.72% |
EPS Q/Q | -42.06% |
Sales Q/Q | 7.05% |
Sales Surprise | 7.55% |
EPS Surprise | 32.03% |
ATR(14) | 2.08 |
Perf Week | 0.78% |
Perf Month | 4.45% |
Perf Quarter | 10.22% |
Perf Year | 17.79% |
Perf YTD | 14.27% |
Target Price | 99.21 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer